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Ke Ji1, Lin Ye1, Fiona Ruge1, Rachel Hargest1, Malcolm D Mason2 and Wen G Jiang1*Abstract
Background: Kiss-1 and Kiss-1R have been suggested as a novel pair of metastasis suppressors for several human
solid tumours, however, their role in colorectal cancer remains largely unknown. Therefore, the aim of this study
was to investigate the role and signal transduction of Kiss-1 and Kiss-1R in colorectal cancer.
Methods: Ribozyme transgenes were used to knockdown high expression of Kiss-1 and Kiss-1R in HT115 and HRT18
cells. The stabilized transfected cells were then used to deduce the influence of Kiss-1 and Kiss-1R on the function of
colorectal cancer cells by in vitro assays and ECIS assay. The effect of Kiss-1 on MMPs related to tumour metastasis was
also deleted by zymography. The mRNA and protein expression of Kiss-1 and Kiss-1R, and their correlation to the
clinical outcome in human colorectal cancer were investigated using real-time PCR and IHC respectively.
Results: Knocking down Kiss-1 resulted in increased invasion and migration of colorectal cancer cells. Kisspeptin-10
decreased cellular migration of colorectal cancer cells and required ERK signaling as shown during the ECIS based
analyses. Reduction of MMP-9 was caused by Kisspeptin-10 and ERK inhibitor, shown by zymography. In human
colorectal cancer tissues, the mRNA expression level of Kiss-1 had a negative correlation with Dukes staging, TNM
staging, tumour size and lymph node involvement. Reduction of Kiss-1R was also linked to poor prognosis for
the patients.
Conclusions: The present study has presented evidence that Kiss-1 may be a putative metastasis suppressor
molecule in human colorectal cancer.
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signal pathwayBackground
Colorectal cancer (CRC) is the second most commonly
diagnosed cancer and is a major cause for mortality and
morbidity globally [1].
The Kiss-1 gene was identified as a human melanoma
metastasis suppressor gene through the analysis of sub-
tractive hybridization in highly metastatic cell lines as
compared to non-metastatic cell lines [2]. The Kiss-1 gene
encodes a protein of 145-amino-acids, which is subse-
quently cleaved into a family of Kisspeptins, including
Kisspeptin-10, Kisspeptin-13, Kisspeptin-14, Kisspeptin-54
respectively [3-5]. Its receptor, Kiss-1R, also known as G-* Correspondence: jiangw@cardiff.ac.uk
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unless otherwise stated.protein coupled receptor 54 (GPR54) was first discovered
and cloned from rat brain in 1999 [6].
Kiss-1 and Kiss-1R have been suggested as a novel pair
of metastasis suppressors in most cancers [5,7-11]. Correl-
ation between decreased expression of Kiss-1 and poor
clinical outcomes has been evident in most malignancies
that have been investigated. One possible explanation
for the role played by Kiss-1 in cancer biology could be
extrapolated from the relationship between Kiss-1 and
matrix metalloproteinases (MMPs), whose significance
in tumour invasion and metastasis formation is well
known [12]. However, few studies have specifically
shown a role for Kiss-1 in colorectal cancer as yet.
In this study, we examined the expression of Kiss-1
and Kiss-1R in human colorectal cancer and analyzed
the potential clinical and prognostic implications. After
that, we investigated their effect on the function ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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these experiments, Kiss-1 may play a metastasis sup-
pressor role in human colorectal cancer and be linked
to the disease progression of patients, by way of aberrant
expression and molecular and cellular mechanism (s) that
are yet to be identified.
Methods
Patients and tissue specimens
Colorectal cancer tissues (n = 94) and normal background
tissues (n = 80) were collected immediately after surgery
with approval by the South East Wales Local Research
Ethics Committee (ref 05/WSE03/92) and patients’ con-
sent. The tissue samples were stored in a deep freezer
(−80°C) until further use. Patients were routinely followed
after surgery and the median follow up period was 120
months. Tumour tissues and normal tissues (>10 cm away
from the tumor margin) were obtained with confirmation
by a pathologist.
Cell culture
HT115 and HRT18 cancer cell lines were obtained from
the European Collection of Animal Cell Culture (ECACC,
Salisbury, England, UK).
Peptide receptors and inhibitors, antibodies
ERK inhibitorII (FR180204) (Calbiochem, Germany),
Kisspeptin-10 (No.2570) (Tocris Bioscience, Bristol, UK)
and Kisspeptin-234 (Tocris Bioscience, Bristol, UK).
Kisspeptin-10, a short peptide of 10 amino acids, is pro-
teolytically processed from Kiss-1 [13]. Kisspeptin-234
is a Kisspeptin-10/Kiss-1R antagonist, which belongs to
Kisspeptin-10 analog. Antibodies to Kiss-1 (SC-101246)
and Kiss-1R (SC-48220) were purchased from Santa
Cruz Biotechnologies Inc., (Santa Cruz, CA, USA).Table 1 Primer sequences used for RT-PCR and Q-PCR in this
Genes Sense (5'-'3)
Kiss-1 Conventional PCR TGAACTCACTGGTTTCTTGG
Quantitative PCR CATTAGAAAAGGTGGCCTCT
Anti-Kiss1 ribozyme1 CTGCAGCTCTCGGGGGGCG
GGGACAGCGAGGTCCCCCC
TGATGAGTCCGTGAGGA
Anti-Kiss-1 ribozyme2 CTGCAGCACCGCGCCCTGGG
CGGGCTGATGAGTCCGTGAG
Kiss-1R Conventional PCR CTTCATGTGCAAGTTCGTC
Quantitative PCR GCTGGTCATCTACGTCATCT
Anti-Kiss-1R ribozyme1 CTGCAGTTCCGCATCGGCTTG
CGGCACTGATGAGTCCGTGA
Anti-Kiss-1R ribozyme2 CTGCAGAGCCTACCCAGATG
AGGCTCTGATGAGTCCGTGA
GAPDH Conventional PCR GGCTGCTTTTAACTCTGGTA
Quantitative PCR CTGAGTACGTCGTGGAGTCRNA isolation, cDNA synthesis, RT-PCR, Q-PCR and
immunohistochemical staining
RNA extraction kits, reverse transcription kits and RT-
PCR Mix were purchased from Promega (WI, USA)
and Bio-Rad (CA, USA). Conventional PCR primers
were designed using Beacon Designer (Palo Alto, CA,
USA) and synthesized by Invitrogen (Paisley, Scotland,
UK). Following the manufacturer’s protocol, total RNA
was isolated using TRI reagent (Sigma). The concentra-
tion of RNA was detected by a UV spectrophotometer
at 260 and 280 nm. cDNA samples were synthesized
and the final reaction volume was 20μl. Primers used
for RT-PCR are given in Table 1, and GAPDH was used
as the house keeping control.
Real-time quantitative PCR, based on the Amplifluor™
technology, was used to quantify the level of mRNA
expression of Kiss-1 and Kiss-1R from the cDNA sam-
ples of coloretal tissues and cells, mentioned above. All
colorectal cDNA samples were synchronously examined
for Kiss-1 and Kiss-1R along with a set of internal
controls. Q-PCR primers (Table 1) were designed using
Beacon Design software (PREMIER Biosoft, Palo Alto,
CA). Real-time PCR was carried out using an IcyclerIQ™
(Bio-Rad, Hemel Hempstead, UK) with the following
cycling conditions: 94°C for 5 min, 80–90 cycles of: 94°C
for 10 sec, 55°C for 35 sec and 72°C for 20 sec.
Frozen sections of colorectal tumours and adjacent
background tissues were sectioned at a thickness of 6
μm using a cryostat . The samples were mounted onto
Super Frost Plus microscope slides (Fisher, UK). The
samples were fixed in a mixture of 50% acetone and 50%
methanol and then air-dried. After rehydration and
blocking with 5% horse serum solution, the sections
were probed with the appropriate primary antibody and
secondary antibodies. Following the instructions, thestudy
Antisense (5'-'3)
CGAAGGAGTTCCAGTTGTAG
ACTGAACCTGACCGTACAGCCCAGGGATTCTAGCTG
ACTAGTGCCAGCTGCTACTGCCAGGCTGAGCCGTTT
CGTCCTCACGGACT
GTG
GA
ACTAGTGTCCGCCCCCCACAGCCGCCAGATTTCGTCC
TCACGGACT
CACCAGGAACAGCTGGAT
ACTGAACCTGACCGTACACAGCACAGGAGGAAGGTC
TGG
GGA
ACTAGTTCGCTGGTCATCTACGTCATTTCGTCCTCACGGACT
CTG
GGA
ACTAGTGCCCCGCCTGGCGCTGGCTGTTTCGTCCTCACGGACT
GACTGTGGTCATGAGTCCTT
ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG
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CA, USA) was applied before staining with diaminobenzi-
dine chromogen. Nuclei were counterstained in Mayer’s
haematoxylin. Sections from fresh frozen human placenta
were used as positive controls.
Generation of Kiss-1 and Kiss-1R ribozyme transgenes
and stable transfectants
Hammerhead ribozymes targeting Kiss-1 and Kiss-1R
were designed using Zuker’s mRNA Fold programme [14]
based on the secondary structure of Kiss-1 and Kiss-1R
mRNA (Figure 1A and B, respectively). The ribozymesFigure 1 Genetic modification of Kiss-1 and Kiss-1R expression in colo
(B) used to design anti-Kiss1 and Kiss-1 ribozymes C and D: Quantitative re
repeats which was normalized against corresponding internal control (GAP
HT115 cells and HRT18 cells using Western blot.were synthesized using touchdown PCR and cloned
into the pEF6/V5-His TOPO TA expression plasmid
vector (Invitrogen, Paisley, UK) according to the proto-
col provided. Ribozyme transgenes and empty plasmids
were transfected into the two colorectal cell lines
HT115 and HRT18 respectively, utilizing an Easyjet
Plus electroporator (EquiBio, Kent, United Kingdom).
Following selection using blasticidin, verified transfec-
tants which lost the expression of Kiss-1 and Kiss-1R
were used in subsequent experiments. During these
experiments, cDNA generated from human placenta
was used as a positive control.n cancer cells. A and B: Secondary structures of Kiss-1 (A) and Kiss-1R
al time PCR showed Kiss-1 (C) and Kiss-1R (D) mRNA volume of three
DH). E and F: Confirmation of Kiss-1 (E) and Kiss-1R (F) knockdown in
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In vitro cell growth assay
Cells were seeded into 96-well plates at 2,500 cells/well, and
cultured using normal media (10% fetal calf serum, 0.1%
antibiotics). The cells were cultured in triplicate for 1, 3 and
5 days. After incubation the cells were fixed in 4% formalin
and stained with 0.5% crystal violet (w/v). The stained crys-
tal violet was then extracted using 10% (v/v) acetic acid,
and the absorbance was determined using a spectropho-
tometer (Bio-Tek, ELx800) at a wavelength of 540 nm.
In vitro cell adhesion assay
A 96-well plate was precoated with 5 μg of Matrigel
(CollaborativeResearch Products, Bedford, Massachusetts,
USA) and allowed to air dry. Following rehydration using
serum free media, 40,000 cells were seeded into each well.
After 40 minutes of incubation, non-adherent cells were
washed off using BSS. The adherent cells were then
fixed with 4% formalin and stained using 0.5% crystal
violet. The number of adherent cells were counted under
a microscope.
In vitro invasion assay
Transwell inserts (with 8 μm pore) were precoated with
50 μg of Matrigel and air dried. Following rehydration,
40,000 cells were seeded into each insert. After incuba-
tion for three days, cells which had invaded through the
matrix and adhered to the other side of the insert were
fixed in 4% formalin, and stained with 0.5% (w/v) crystal
violet. The number of invaded cells was then counted
under a microscope.
In vitro wounding assay for cellular migration
Cells were seeded into a 24-well plate at a density of
200,000 per well and allowed to form a monolayer of
cells. The monolayer of cells was then scraped to create
a wound. Migration of cells at the wound edges were
monitored over a period up to 18 hours. Optimas 6.0
motion analysis (Meyer Instruments, Houston, Texas)
was used to track the leading edge of cells to measure
the distance of migration.
Electric cell-substrate impedance sensing (ECIS)
The ECIS system (Ztheta, Applied Biophysics Inc., USA)
was used to quantify cell migration as previously reported
by Jiang et al. [15]. HT115 cells were prepared for six
repeats per group and seeded at 40,000 cells per well in
200 μl of DMEM medium alone or medium supplemented
with 200 nM ERK small inhibitor, 300 nM Kisspeptin-10
and 300 nM Kisspeptin-234.
Gelatin zymography assay
Cells were counted and 1×106 cells were seeded to a tissue
culture flask. After an overnight incubation and 4 hourstreatment with appropriate peptide receptor or inhibitor
(300 nM Kisspeptin-10, 300 nM Kisspeptin-234 or 200 nM
ERK inhibitor), the medium was collected. This method is
well established within the laboratory, and has previously
been published [16].
Data analysis
The relationship between the expression of Kiss-1 and
Kiss-1R and tumour grade, TNM staging and nodal status
was respectively analyzed using Mann–Whitney U test
(Tables 2 and 3). Quantitative data of IHC, in vitro assays,
ECIS assay and zymography assay was analyzed using the
Student’s test, Kruskal-Wallis and chi-squared test, where
appropriate. Survival analysis and multivariate analysis were
carried out using the SPSS20 software package. Differences
were considered to be statistically significant at p < 0.05.
Results and discussion
Kiss-1 and Kiss-1R expression in colorectal adenocarcinoma
tissues and the histopathological/clinical characteristics of
the disease
Kiss-1 and Kiss-1R expression was analysed in colorectal
cancer tissues and adjacent normal tissues using real
time PCR (Tables 2 and 3). Decreased levels of Kiss-1
transcript were seen in Dukes B and C tumours compared
with Dukes A carcinomas (p < 0.05). The expression level
of Kiss-1 decreased as TNM stage progressed, and statis-
tical analysis revealed significant links between TNM
stage I and stage III&IV. A significantly decreased ex-
pression of Kiss-1R was observed in tumour tissues
compared with normal background tissues. Interestingly,
Kiss-1R expression in patients undergoing chemo-radio
therapy was considerably higher in comparison to that in
patients without therapy.
A significant difference was also observed in the
expression levels between living patients and those who
had died. The average copy numbers of Kiss-1 and
Kiss-1R transcripts in Dukes B were then employed as
the respective thresholds for the survival analysis. Kaplan-
Meier survival analysis demonstrated that patients with a
low expression level of Kiss-1 appeared to have similar
overall survival and disease free survival compared to
patients with high expression of Kiss-1 (p > 0.05). In
contrast to Kiss-1, the expression pattern of Kiss-1R
revealed that high levels of Kiss-1R transcript are associated
with both a poor overall survival (Figure 2C, p = 0.0011)
and poor disease free survival (Figure 2D, p = 0.0033).
Multivariate analyses have further demonstrated that T-
stage and Kiss-1R are independent prognostic factors
(p = 0.025 and p = 0.003, respectively) for colorectal related
death. Furthermore, TNM staging and Kiss-1R (p = 0.03
and p = 0.012, respectively) are independent prognostic
factors for colorectal cancer related incidence (death,
recurrence and metastasis) (Table 4).
Table 2 The correlation of mRNA expression of Kiss-1 and clinical parameters
Category No. Median IQR p Pa
T/Nb
Normal 80 97 6-2345
Tumour 94 35 1-2108 0.3775
Paired T/Nb
Paired normal 68 82 6-2344
Paired tumour 68 8 0-1855 0.1672
Location
Left colon 22 624 173-1968
Right colon 28 719 44-2000 0.899
Transcolonc 2 154 N/A 0.958
Rectum 22 673 175-2522 0.907
Dukes classification
A 7 5539 848-24856
B 33 780 104-2272 0.043d
C 32 611 190-1221 0.015d
Tumour stage
T1 2 8000 N/A
T2 10 1721 789-10369 1
T3 40 639 71-1332 0.226 0.0381d
T4 18 592 215-1600 0.186
Lymph node involvement
Node 0e 39 872 213-2874
Node 1e 16 715 67-1428 0.326
Node 2e 15 609 200-643 0.045d
TNM staging
I 9 2081 814-20038
II 30 756 122-2473 0.06
III&IV 32 611 190-1221 0.009d
Clinical outcome
No invasion 50 835 127-2372
Invasion 26 579 161-948 0.1907
Disease free 35 759 84-2081
Incidence 23 635 217-2187 0.8115
No recurrence 58 735 89-2373
Local recurrence 7 643 269-3718 0.604
No metastasis 50 735 84-2522
Metastasis 19 634.3 213-1463 0.92
Alive 36 661 86-1876
Death 22 572 195-1644 0.923
aTumour (T), Normal (N). bTransverse colon. cp < 0.05. dNode 0 stands for no node involvement; Node 1 stands for 1 to 3 lymph nodes close to the bowel found
to contain cancer cells; Node 2 stands for more than 3 lymph nodes found to contain cancer cells and further than 3cm away from the main tumor in the bowel
or the presence of cancer cells in lymph nodes connected to the main blood vessels around the bowel.
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of paired normal and tumour tissues (n = 23 pairs). Intense
expression of Kiss-1 and Kiss-1R was primarily observed inthe cytoplasm of epithelial cells in adjacent normal tissues
compared with cancer cells (p value < 0.05), as shown in
Figure 2A and B.
Table 3 The correlation of mRNA expression of Kiss-1R and clinical parameters
Category No. Median IQR p
T/Na
Normal 80 30 1-2406
Tumour 94 <0.000001 <0.000001 <0.0001c
Paired T/Na
Paired normal 68 23 0-522
Paired tumour 68 <0.000001 0-0.02 <0.0001c
Location
Left colon 22 <0.000001 <0.000001-0.01
Right colon 28 <0.000001 <0.000001-0.009 0.8791
Transcolonb 2 0.00452 N/A
Rectum 22 <0.000001 <0.000001-0.13 0.447
Dukes classification
A 7 0.00015 <0.000001-0.00103
B 33 0.0004 <0.000001-0.0091 0.6616
C 32 <0.000001 <0.000001-0.09 0.1431
Tumour stage
T1 2 1.06E-05 N/A
T2 10 0.00005 <0.000001-0.00171
T3 40 <0.000001 <0.000001-0.03
T4 18 <0.000001 <0.000001-0.02
Lymph node involvement
Node 0d 39 0.0003 <0.000001-0.0071
Node 1d 16 <0.000001 <0.000001-0.02 0.3236
Node 2d 15 0.01 <0.000001-1.76 0.335
TNM staging
I 9 0.00003 <0.000001-0.00033
II 30 0.0005 <0.000001-0.0105 0.1939
III&IV 32 <0.000001 <0.000001-0.09 0.051
Clinical outcome
No invasion 50 <0.000001 <0.000001-0.008
Invasion 26 <0.000001 <0.000001-0.05 0.1907
Disease free 35 0.00019 <0.000001-0.00523
Incidence 23 0.01 <0.000001-0.12 0.0207c
No recurrence 58 <0.000001 <0.000001-0.013
Local recurrence 7 0.00653 <0.000001-0.02245 0.6923
No metastasis 50 <0.000001 <0.000001-0.009
Metastasis 19 <0.000001 <0.000001-0.13 0.0765
Alive 36 0.00028 <0.000001-0.00724
Death 22 <0.000001 <0.000001-0.13 0.0158c
Non treat 42 0.0002 <0.000001-0.006
Chemradio 5 0.0796 0.012-0.1607 0.0115c
aTumour (T), Normal (N). bTransverse colon. cp < 0.05. dNode 0 stands for no node involvement; Node 1 stands for 1 to 3 lymph nodes close to the bowel found to
contain cancer cells; Node 2 stands for more than 3 lymph nodes found to contain cancer cells and further than 3cm away from the main tumor in the bowel or
the presence of cancer cells in lymph nodes connected to the main blood vessels around the bowel.
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Figure 2 Expression of Kiss-1 and Kiss-1R in colorectal cancer. A. Immunohistochemical staining of Kiss-1 and Kiss-1R in normal colorectal tissue
and tumour tissue; Arrows point to the staining of Kiss-1 and Kiss-1R in the cytoplasm of normal cells. Placenta was used as the positive control for
both Kiss-1 and Kiss-1R. B. Semi quantitative analysis used to verify the protein expression level of Kiss-1 and Kiss-1R protein in normal background and
tumour tissue. C. Kaplan- Meier survival analysis displaying relationship between the transcript levels of Kiss-1R and overall survival. D. Kaplan- Meier
survival analysis displaying the relationship between the transcript levels of Kiss-1R and disease free survival. Patients with high levels of Kiss-1R had a
significantly shorter overall survival being 85.8 months (95% C.I. 49.9- 121.6 months), p = 0.011 in comparison to those with low levels (143.0 months,
95% C.I. 124.261- 161.712). The patients with lower expression of Kiss-1R also had longer disease free survival (median = 133.2 months, 95%
C.I. 111.7- 154.7 months), p = 0.033 compared with those with higher expression levels (median = 88.3 months, 95% C.I. 50.1- 126.6).
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effect on functions of colorectal cancer cells
The expression of Kiss-1 and Kiss-1R in both HT115
and HRT18 cells transfected with corresponding
ribozyme transgenes was examined using conven-Table 4 Multivariate analysis for prognostic factors for
colorectal related death and incidence (p values)
Variables With colorectal
related death
With colorectal
related incidence
Dukes stage 0.507 0.249
T-stage 0.025 0.092
TNM stage 0.146 0.030
Node status 0.230 0.057
Differentiation 0.601 0.326
Kiss-1 0.435 0.566
Kiss-1R 0.003 0.012tional PCR, real time PCR and Western blot (Figures 1
and 3A).
Analysis of the in vitro function assays revealed cells
with Kiss-1 knockdown had significantly increased inva-
siveness (p = 0.015) and migration (p = 0.0094) compared
HT115 pEF cells (Figure 3B and C), but knockdown of
Kiss-1 and Kiss-1R did not demonstrate a significant
change on cell growth and adhesion of HT115 and
HRT18 cells (p > 0.05).
Effect of Kiss-1 and Kiss-1R knockdown on the motility of
the cancer cells and the involvement of ERK pathway
HT115 Kiss-1 knockdown cells treated with Kisspeptin-
10 had a significant decrease in motility compared to
the control cells (Figure 4A), but no significant dif-
ference was observed between control and Kiss-1R
knockdown cells. In contrast, neither Kiss-1 knockdown
or Kiss-1R knockdown cells treated with Kisspeptin-
Figure 3 Knockdown of Kiss-1 altered functions of colorectal cancer cells. A. RT-PCR displayed a reduced mRNA expression level of Kiss-1 and
Kiss-1R in HT115/ HRT18 Kiss-1 knockdown cells and HT115/ HRT18 Kiss-1R knockdown cells compared with control cells (WT and pEF) respectively.
Placenta was used as a positive control for both Kiss-1 and Kiss-1R (far right panel). B. Left: The influence of Kiss-1 and Kiss-1R knockdown on the
invasive capability of HT115 cells (left) and HRT18 cells (right). Three representative images of cells following staining are shown in the top. Data shown
is the mean value of 3 repeats of experiment. C. The effect of Kiss-1 and Kiss-1R knockdown on the migration ability of HT115 cells (left) and HRT18
cells (right). Data shown is the mean value of 3 repeats of experiment. Error bars represent standard deviation. * stands for p < 0.05.
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groups (no treatment) (p > 0.05) (Figure 4B). The ad-
herence of Kiss-1 knockdown cells treated with ERK
inhibitor significantly decreased compared with that
of the control group (no treatment) after wounding
(p = 0.0397) (Figure 4C). A similar effect was also
observed in the comparison between the control group(no treatment) and cells treated with ERK inhibitor +
Kisspeptin-234 (Figure 4E). In contrast to the groups
treated with ERK inhibitor or ERK inhibitor together
with Kisspeptin-234, there were more striking links
between the Kiss-1 knockdown cells treated with ERK
inhibitor + Kisspeptin-10 and its control (no treatment)
(p = 0.0164) (Figure 4D).
Figure 4 (See legend on next page.)
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Figure 4 ERK pathway in the Kiss-1 regulated motility of colorectal cancer cells. A. Left: The effect of Kiss-1 and Kiss-1R knockdown on the
migration ability of HT115 cells treated withKisspeptin-10 compared with control group (no treatment). Right: Overall changes in resistance at the
eighth hour * p < 0.05 vs the respective control group at the specific time point. B. Left: Cells in two different experimental settings (control and
Kisspeptin-234) during 8 hours after wounding. Right: Overall changes in resistance at the eighth hour. C. Left: The mean trace of the cells in two
groups of experiments (control and ERK inhibitor) 8 hours after wounding. Right: Overall changes in resistance at the eighth hour. D. Left: Cell
responses after wounding (control and ERK inhibitor + Kisspeptin-10) during 8 hours after wounding. Right: Overall changes in resistance at the
eighth hour. E. Left: Cells responses in different experimental settings, namely control and ERK inhibitor + Kisspeptin-234, over an 8 hours period
after wounding. Right: Overall changes in resistance at the eighth hour.
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Kiss-1/Kiss-1R and ERK pathway
MMP-9 expression levels were evaluated in three pairs
of HT115 cells (pEF and Kiss-1 knockdown), which were
treated with three different treatments (no treatment,
ERK inhibitor, ERK inhibitor and Kisspeptin-10) (Figure 5).
The weakest expression of MMP-9 was observed in
the cells treated with ERK inhibitor and Kisspeptin-10
(Figure 5A). We further explored the influence of Kiss-1
knockdown together with treatment of Kisspeptin-10 and
234 on MMP-9 and MMP-2 activity, together with the
inhibition of the ERK pathway in the HT115 cell line.
Cells were divided into three treatment groups, namely no
treatment (control group), Kisspeptin-10, and Kisspeptin-
234 respectively. For each group, two pairs of HT115 pEF
and HT115 Kiss-1 knockdown cells were treated with or
without ERK inhibitor, namely + ERK inhibitor and control
respectively (Figure 5B). Figure 5C shows expression of
Kiss-1 and treatment of the cells with the inhibitors had a
greater impact on the enzyme activity of MMP-9 than
on that of MMP-2. Hence, the difference in MMP-9
expression in HT115 cells was chosen to analyze further.
Figure 5D shows the difference in the enzyme activity of
MMP-9 in HT115 pEF (left) and Kiss-1 knockdown (right)
cells of all three groups (no treatment, Kisspeptin-10
and Kisspeptin-234). The enzyme activity of MMP-9 in
HT115 pEF cells treated with ERK inhibitor was sig-
nificantly inhibited compared with that of controls in
all three groups. Similarly, with HT115 pEF cells, the
enzyme activity of MMP-9 in HT115 Kiss-1 knock-
down cells treated with ERK inhibitor brought about a
strong inhibition in comparison to the controls in the
groups of no treatment (p = 0.00017) and Kisspetin-10
(0.001544) (Figure 5D). Furthermore, the results show
that both HT115 cells treated with Kisspeptin-10
exhibited a decreased expression of MMP-9 in com-
parison to the cells treated with serum free medium
and Kisspeptin-234.
Conclusions
The expression of Kiss-1 correlated significantly with Dukes
classification, TNM staging, tumour stage and lymph node
involvement. Interestingly, these stages are classified by
the level of tumour invasion and metastasis. Hence, theconclusion from the clinical cohort was consistent with
studies in other malignancies. Kiss-1 has a significant,
and negative correlation with tumour metastasis and
invasion. Loss of Kiss-1R expression was significantly
associated with disease free survival, since increased
expression of Kiss-1R may have positive correlation
with survival. Moreover, high expression of Kiss-1R
transcripts was associated with poor prognosis in both
overall survival and disease free survival compared with
low expression of Kiss-1R. Aberrant Kiss-1 and Kiss-1R
expression is definitely a point for consideration. One
hypothesis to explain this may be that the inhibitory
effect of Kiss-1 on colorectal cancer cells may not solely
combine with Kiss-1R, but with other unknown receptors.
Navenot et al. reported Kiss-1/Kiss-1R also influenced sig-
naling events by interacting with the chemokine receptor
(CXCR4) and the gonadotrophin-releasing hormone
receptor [17]. Kiss-1R knockdown has little effect on cell
migration compared with the control cells which may
support this hypothesis. Finally, a recent report has
shown that the reduction/loss of Kiss-1 in colorectal
cancer may be the result of hypermethylation of Kiss-1,
and this provides a plausible explanation for the reduc-
tion of Kiss-1 observed in the current study [18]. It will
be interesting to explore the mechanisms by which
Kiss-1R is reduced/lost in this cancer type in the future.
Data obtained from the present study suggests that
Kiss-1 significantly inhibits the motility and invasion of
HT115 and HRT18 colorectal cancer cells, but has no
significant effect on the proliferation and adhesion of
HT115 and HRT18 cells. Interestingly, no increase in
cell migration of Kiss-1R knockdown cells compared
with the controls was observed. The motility of Kiss-1R
knockdown cells would increase the same as the Kiss-1
knockdown cells did, if Kiss-1 indeed had the inhibitory
influence on cell migration through Kiss-1R.
Several studies have suggested the mechanism by which
Kiss-1 inhibits metastasis may involve extracellular-
regulated kinase 1/2 (ERK1/2) phosphorylation and de-
creased matrix metalloproteinase-2 (MMP-2) expression
[11,19,20]. In addition, Yan et al. reported Kisspeptin-10/
Kiss-1R activation can dephosphorylate nuclear factor
kappa B (NF-Kappa B), and cause it to dissociate from the
MMP-9 promoter. This process ultimately results in a
Figure 5 Kiss-1 expression had an significant impact on MMP-9. A and B. The overall MMP-9 gene expression was increased in HT115 Kiss-1
knockdown cells as shown by RT-PCR (A) and by real-time quantitative PCR (B). C. The enzyme activity of MMP-9 and MMP-2 in HT115 pEF and
HT115 Kiss-1 knockdown cells, following treatment (no treatment, Kisspeptin-10 and Kisspeptin-234). (cells + ERK inhibitor vs control in the group
of no treatment: p = 0.006577; cells + ERK inhibitor vs control in the group of Kisspeptin-10: p = 0.001839; cells + ERK inhibitor vs control in the
group of Kisspeptin-234: p = 0.005935). D. The difference between MMP-9 enzyme activity in three groups of HT115 pEF cells (left) and HT115
Kiss-1 knockdown cells (right). + represents for corresponding treatment. Experiment was repeated three times and mean value taken.
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http://www.biomedcentral.com/1471-2407/14/723decrease of MMP-9 expression in the placenta [21]. It
will indeed be very interesting to examine the degradation
of NF-Kappa B in response to Kiss-1 signalling in future
studies. As a contribution to this endeavor, we have
examined the effects of Kisspeptin-10 and ERK inhibitor
on the migration ability of HT115 cells using ECIS assays,
and found it to suppress the migration of colorectal
cancer cells. Addition of ERK inhibitor can diminish
the effect of Kisspeptin-10, suggesting the ERK pathwayplays an important role in mediating the signaling of
Kiss-1/Kiss-1R.
Kiss-1 significantly inhibits the motility and invasion
of HT115 cells. It is clear this action is at least partly
mediated by regulating the activity of MMP-9. This study
further indicates that the effect on MMP-9 is via the ERK
pathway rather than the JNK pathway. In summary, it is
suggested Kiss-1 inhibits ERK activation and consequently
reduces the enzymatic activity of MMP-9 caused by the
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sion of tumour metastasis.
Perhaps the most intriguing property of Kiss-1 is its
potential to be exploited clinically. In the future we are
interested in investigating the influence of Kisspeptin-10
on tumour growth and metastasis in an in vivo tumour
model. Furthermore, Ziegler et al. reported that anti-
proliferative function of Kisspeptin-10 was regulated by
the expression levels of Kiss-1R [22]. There was no effect
on proliferation observed in the breast cancer cells
expressing Kiss-1R endogenously, while Kisspeptin-10
caused a significant inhibition of proliferation of trans-
fected neuronal cells over-expressing Kiss-1R [22]. Hence,
detecting the influence of Kisspeptin-10 on colorectal
cancer through changing Kiss-1R’s expression levels will
be the focus of follow-up studies.
In conclusion, the present study has presented evidence
that Kiss-1 is a putative metastasis suppressor molecule in
human colorectal cancer. This is seen by its inhibitory
effect on the migration and invasion of colorectal cancer
cells, and on actions achieved by down-regulating the
activities of MMP9, via an ERK dependent pathway.
The preliminary data from studies on a clinical cohort
of colorectal cancer patients support this argument.
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